肝硬化并发感染的机制研究现状

摘要/Abstract

摘要： 肝硬化是慢性肝脏疾病的终末期阶段,肝组织呈弥漫性纤维化表现。在肝硬化失代偿期可有肝功能低下、门静脉高压、脾大及脾功能亢进等临床表现。同时这些临床特征也是肝硬化容易并发感染的因素,因而从肝功能、门静脉高压、脾功能亢进等与免疫的关系入手,对肝硬化并发感染的机制作一综述,以期及早发现感染,及时处理,改善预后。

王希, 谭善忠. 肝硬化并发感染的机制研究现状[J]. 肝脏, 2022, 27(1): 120-122.

[1] 中华医学会肝病学分会. 肝硬化诊治指南. 中华肝脏病杂志, 2019, 27: 846-865.
[2] Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, 2017, 390: 1151-1210.
[3] Fernández J, Prado V, Trebicka J, et al. Multidrug-resistant bacterial infections in patients with decompensated cirrhosis and with acute-on-chronic liver failure in Europe. J Hepatol, 2019, 70: 398-411.
[4] Hsu YC, Yang YY, Tsai IT. Lymphocyte-to-monocyte ratio predicts mortality in cirrhotic patients with septic shock. Am J Emerg Med, 2021, 40:70-76.
[5] Basho K, Zoldan K, Schultheiss M, et al. IL-2 contributes to cirrhosis-associated immune dysfunction by impairing follicular T helper cells in advanced cirrhosis. J Hepatol, 2021, 74: 649-660.
[6] Lebossé F, Gudd C, Tunc E, et al. CD8(+)T cells from patients with cirrhosis display a phenotype that may contribute to cirrhosis-associated immune dysfunction. EBioMedicine, 2019, 49:258-268.
[7] Tuchendler E, Tuchendler PK, Madej G. Immunodeficiency caused by cirrhosis. Clin Exp Hepatol, 2018, 4: 158-164.
[8] Abbas AK, Trotta E, R Simeonov D, et al. Revisiting IL-2: biology and therapeutic prospects. Sci Immunol,2018, 3:eaat1482.
[9] Wu T, Shin HM, Moseman EA, et al. TCF1 is required for the T follicular helper cell response to viral infection. Cell Rep, 2015, 12: 2099-2110.
[10] Dirchwolf M, Podhorzer A, Marino M, et al. Immune dysfunction in cirrhosis: distinct cytokines phenotypes according to cirrhosis severity. Cytokine, 2016, 77:14-25.
[11] Mouillaux J, Allam C, Gossez M, et al. TCR activation mimics CD127lowPD-1highphenotype and functional alterations of T lymphocytes from septic shock patients. Crit Care,2019, 23: 131.
[12] Tripathi A, Debelius J, Brenner DA, et al. The gut-liver axis and the intersection with the microbiome. Nat Rev Gastroenterol Hepatol,2018, 15: 397-411.
[13] Solé C, Guilly S, Da Silva K, et al. Alterations in gut microbiome in cirrhosis as assessed by quantitative metagenomics: relationship with acute-on-chronic liver failure and prognosis. Gastroenterology, 2021, 160: 206-218.
[14] Jalan R, Fernandez J, Wiest R, et al. Bacterial infections in cirrhosis: a position statement based on the EASL Special Conference 2013. J Hepatol, 2014, 60: 1310-1324.
[15] Trebicka J, Reiberger T, Laleman W. Gut-Liver axis links portal hypertension to acute-on-chronic liver failure. Visc Med, 2018, 34: 270-275.
[16] Tripathi DM, Vilaseca M, Lafoz E, et al. Simvastatin prevents progression of acute on chronic liver failure in rats with cirrhosis and portal hypertension. Gastroenterology, 2018, 155: 1564-1577.
[17] Hackstein CP, Assmus LM, Welz M, et al. Gut microbial translocation corrupts myeloid cell function to control bacterial infection during liver cirrhosis. Gut, 2017, 66: 507-518.
[18] Asanoma M, Ikemoto T, Mori H, et al. Cytokine expression in spleen affects progression of liver cirrhosis through liver-spleen cross-talk. Hepatol Res, 2014, 44: 1217-1223.
[19] Ren S, Zhang S, Li M, et al. NF-κB p65 and c-Rel subunits promote phagocytosis and cytokine secretion by splenic macrophages in cirrhotic patients with hypersplenism. Int J Biochem Cell Biol, 2013, 45: 335-343.
[20] Jiang A, Zhang S, Li Z, et al. miR-615-3p promotes the phagocytic capacity of splenic macrophages by targeting ligand-dependent nuclear receptor corepressor in cirrhosis-related portal hypertension. Exp Biol Med, 2011, 236: 672-680.
[21] Fair KA, Connelly CR, Hart KD, et al. Splenectomy is associated with higher infection and pneumonia rates among trauma laparotomy patients. Am J Surg, 2017, 213: 856-861.
[22] Nomura Y, Kage M, Ogata T, et al. Influence of splenectomy in patients with liver cirrhosis and hypersplenism. Hepatol Res, 2014, 44: E100-109.
[23] 纪泛扑, 黄娜, 张澍,等. 脾切除对丙型病毒性肝炎后肝硬化门静脉高压症患者细胞免疫功能的影响. 中华肝脏外科手术学电子杂志, 2015, 4: 232-236.
[24] Rosenblatt R, Atteberry P, Tafesh Z, et al. Uncontrolled diabetes mellitus increases risk of infection in patients with advanced cirrhosis. Dig Liver Dis, 2021, 53: 445-451.
[25] Elkrief L, Chouinard P, Bendersky N, et al. Diabetes mellitus is an independent prognostic factor for major liver-related outcomes in patients with cirrhosis and chronic hepatitis C. Hepatology, 2014, 60: 823-831.
[26] Bernardi M, Angeli P, Claria J, et al. Albumin in decompensated cirrhosis: new concepts and perspectives. Gut,2020, 69: 1127-1138.

肝硬化并发感染的机制研究现状

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	冯丽娟, 贾继东. 关于肝硬化并发症诊治的共识与争议[J]. 肝脏, 2022, 27(1): 4-7.
[2]	王昱, 张春盼, 王艳, 刘立伟, 李轲鑫, 马子坤, 贾继东, 王伽伯, 赵新颜. 制何首乌对CTLA-4抗体诱导的PD-1^-/-小鼠肝损伤模型的改善作用[J]. 肝脏, 2022, 27(1): 33-37.
[3]	王育光, 刘志威. 信息化随访干预措施对HBV感染患者依从性影响分析[J]. 肝脏, 2022, 27(1): 38-41.
[4]	黎妮, 黄裕林, 马世河. 血Tim-3联合γ-GT/胆碱酯酶比值在转氨酶正常或轻度升高慢性乙型肝炎患者中的临床价值[J]. 肝脏, 2022, 27(1): 42-46.
[5]	张昕, 吕丹, 刘丹阳. 肝硬化食管胃底静脉曲张破裂出血伴缺血性肝炎的危险因素分析[J]. 肝脏, 2022, 27(1): 47-50.
[6]	肖琨, 刘爱华, 刘琨. 超声测量静脉内径在血吸虫肝硬化及乙型肝炎肝硬化鉴别中的应用[J]. 肝脏, 2022, 27(1): 51-53.
[7]	李旭东, 范锡伟, 王丽, 郭振凯. HBV相关慢加急性肝衰竭出血事件预后评价及影响因素分析[J]. 肝脏, 2022, 27(1): 68-71.
[8]	王鑫, 张国民, 牛兴杰, 李萍, 张冰. 外周血NLR、nCD64在HBV相关ACLF继发感染和短期预后中的诊断及预测价值[J]. 肝脏, 2022, 27(1): 72-75.
[9]	王秋, 林川. 糖尿病合并原发性肝癌患者介入术后感染发生状况及其影响因素分析[J]. 肝脏, 2022, 27(1): 76-80.
[10]	冯丹妮, 张达利, 贺希, 张晓峰, 牛晓峰, 李志杰, 李丽昕, 刘佳, 庄云龙, 刘振文, 王洪波. 肝移植术后新发非酒精性脂肪肝的危险因素[J]. 肝脏, 2022, 27(1): 95-97.
[11]	张丽丽, 胡建华, 张纯, 杨君, 吕文良. 酒精性肝硬化合并强直性脊柱炎并存类风湿关节炎1例[J]. 肝脏, 2022, 27(1): 124-125.
[12]	张云, 尹伟, 郭洪雷, 李成忠. 新型生物学标志物在肝硬化AKI早期诊断和鉴别诊断中的研究进展[J]. 肝脏, 2021, 26(9): 953-955.
[13]	潘国栋, 侯斐, 张瑶, 刘玉凤, 王晓静, 刘尧, 段英, 王艳斌, 李炜, 郝一炜, 熊号峰. 右心声学造影在肝硬化患者肺内血管分流评价中的应用[J]. 肝脏, 2021, 26(9): 972-976.
[14]	黎美琳, 姚上志, 王栋, 居峰, 王晓伟. 卡维地络联合内镜下精准食管胃静脉曲张断流术治疗食管胃静脉曲张破裂出血的疗效[J]. 肝脏, 2021, 26(9): 980-983.
[15]	陈衍磊, 蔡永国. 超声内镜下内镜黏膜剥离术在乙型肝炎肝硬化患者食管良性肿瘤中的可行性研究[J]. 肝脏, 2021, 26(9): 984-986.